In the current study, we investigated the effect of growth of FasL(+)
tumors in vivo on the functions of peripheral lymphoid organs and the liver. Injection of FasL(+) LSA
tumor cells into syngeneic C57BL/6 wild-type mice but not C57BL/6 lpr/lpr (Fas-deficient) mice caused apoptosis in splenocytes. Spleen cells expressing CD3, CD4, CD8, CD19,
Mac-3, and CD44 were all susceptible to
tumor-induced apoptosis. Also, activated T cells were more sensitive to apoptosis induced by LSA
tumor cell lysate when compared to naïve T cells. In contrast, anti-Fas Abs (Jo2) induced apoptosis in only activated but not naïve T cells. When the LSA
tumor-bearing mice were injected with a
superantigen (SEA), these mice showed a significant decrease in the expansion of SEA-reactive Vbeta3(+) and Vbeta11(+) T cells. When injected into syngeneic mice, the FasL(+) LSA
tumor cells caused hepatotoxicity, as indicated by an increase in serum
aspartate aminotransferase (AST) levels. Interestingly, Fas-deficient C57BL/6 lpr/lpr mice also showed significant AST levels in the serum following LSA
tumor growth. Moreover, hepatocytes isolated from C57BL/6 wild-type and C57BL/6 lpr/lpr mice were equally susceptible to apoptosis induced by LSA
tumor cell lysate in vitro. Using
cDNA array, LSA
tumor cells were found to express several
cytokine genes including
IL-2,
IL-7,
IL-11,
IL-13,
IL-16,
lymphotoxin beta, and
tumor necrosis factor beta. Together, these data suggested that, in mice bearing FasL(+) LSA
tumor, the immunotoxicity is FasL-based, whereas the hepatotoxicity, at least in part, may be FasL-independent.